Results 21 to 30 of about 3,492,883 (216)

BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment. [PDF]

Cancer Biol Ther, 2020
EGFR-TKIs such as erlotinib and gefitinib have been introduced into the first-line treatment for patients having a mutation of deletion in exon 19 or L858R missense mutations in exon 21.
Wang F, Zhang L, Sai B, Wang L, Zhang X, Zheng L, Tang J, Li G, Xiang J.   +8 more
europepmc   +2 more sources

Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells. [PDF]

Sci Rep, 2020
In non-small-cell lung cancer, mutation of epidermal growth factor receptor (EGFR) stimulates cell proliferation and survival. EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib are used as first-line therapy with drastic and immediate ...
Lin Y, Higashisaka K, Shintani T, Maki A, Hanamuro S, Haga Y, Maeda S, Tsujino H, Nagano K, Fujio Y, Tsutsumi Y.   +10 more
europepmc   +2 more sources

Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. [PDF]

Theranostics, 2019
Background: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted therapy. Recently, aldehyde dehydrogenase 1 (ALDH1)
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L.   +9 more
europepmc   +2 more sources

Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC. [PDF]

Cell Prolif, 2019
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) has significant therapeutic efficacy in non‐small‐cell lung cancer (NSCLC) patients. However, acquired resistance is inevitable and limits the long‐term efficacy of EGFR‐TKI. Our study
Wang J, Zhou P, Wang X, Yu Y, Zhu G, Zheng L, Xu Z, Li F, You Q, Yang Q, Zhuo W, Sun J, Chen Z.   +12 more
europepmc   +2 more sources

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.

PLoS ONE, 2012
Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent against cancer due to its relatively low side-effect profile and, at times, greater efficacy.
Jasmine G Lee, Reen Wu
doaj   +4 more sources

Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Molecular Oncology, 2015
Despite the role of epidermal growth factor receptor (EGFR) signaling in head and neck squamous cell carcinoma (HNSCC) development and progression, clinical trials involving EGFR tyrosine kinase inhibitors (TKIs) have yielded poor results in HNSCC ...
Aditya Stanam, Laurie Love-Homan, Tisha S. Joseph, Madelyn Espinosa-Cotton, Andrean L. Simons   +4 more
doaj   +2 more sources

Hexane Fraction of Adenophora triphylla var. japonica Root Extract Inhibits Angiogenesis and Endothelial Cell-Induced Erlotinib Resistance in Lung Cancer Cells [PDF]

Molecules
The aim of this study was to investigate the anti-angiogenic effects of the hexane fraction of Adenophora triphylla var. japonica root extract (HAT) and its influence on the development of erlotinib resistance in human lung cancer cells.
Hyun-Ji Park, Jae-Hoon Jeong, Yung-Hyun Choi, Shin-Hyung Park   +3 more
doaj   +2 more sources

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase. [PDF]

Theranostics, 2018
How to improve the efficacy and reverse the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of lung adenocarcinoma with EGFR-activating mutation ...
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y.   +13 more
europepmc   +2 more sources

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

Scientific Reports, 2017
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients.
Jinrong Liao, Jinghui Lin, Dong Lin, Changyan Zou, Jessica Kurata, Renjang Lin, Zhiyong He, Ying Su   +7 more
doaj   +2 more sources

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers. [PDF]

Cell Death Dis, 2018
Acquired resistance to epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a critical obstacle in the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC).
Wang X, Yin H, Zhang H, Hu J, Lu H, Li C, Cao M, Yan S, Cai L.   +8 more
europepmc   +2 more sources